CD4 and systemic lupus erythematosus: Thus, the present study highlights that MSCT exerts an early neuroprotective effect in lupus by decreasing the number of systemic IFN-γ–producing CD4+ T (Th1) cells and reducing the entrance of IFN-γ into the brain.